Commonwealth Equity Services LLC Raises Holdings in ABIOMED, Inc. (ABMD)

Commonwealth Equity Services LLC boosted its position in shares of ABIOMED, Inc. (NASDAQ:ABMD) by 52.3% in the fourth quarter, according to the company in its most recent filing with the SEC. The firm owned 5,476 shares of the medical equipment provider’s stock after acquiring an additional 1,881 shares during the quarter. Commonwealth Equity Services LLC’s holdings in ABIOMED were worth $1,779,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Robeco Institutional Asset Management B.V. boosted its position in shares of ABIOMED by 57.1% in the third quarter. Robeco Institutional Asset Management B.V. now owns 44,111 shares of the medical equipment provider’s stock valued at $19,838,000 after acquiring an additional 16,025 shares during the period. US Bancorp DE boosted its position in shares of ABIOMED by 98.8% in the third quarter. US Bancorp DE now owns 2,169 shares of the medical equipment provider’s stock valued at $976,000 after acquiring an additional 1,078 shares during the period. Wells Fargo & Company MN boosted its position in shares of ABIOMED by 6.0% in the third quarter. Wells Fargo & Company MN now owns 142,616 shares of the medical equipment provider’s stock valued at $64,141,000 after acquiring an additional 8,074 shares during the period. Virginia Retirement Systems ET AL boosted its position in shares of ABIOMED by 20.0% in the third quarter. Virginia Retirement Systems ET AL now owns 1,800 shares of the medical equipment provider’s stock valued at $810,000 after acquiring an additional 300 shares during the period. Finally, Sumitomo Mitsui Trust Holdings Inc. boosted its position in shares of ABIOMED by 6.5% in the third quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 153,544 shares of the medical equipment provider’s stock valued at $69,056,000 after acquiring an additional 9,393 shares during the period. 86.96% of the stock is owned by institutional investors.

ABMD opened at $325.61 on Friday. ABIOMED, Inc. has a twelve month low of $274.02 and a twelve month high of $459.75. The stock has a market cap of $14.66 billion, a P/E ratio of 132.90, a PEG ratio of 3.27 and a beta of 0.37.

ABIOMED (NASDAQ:ABMD) last posted its quarterly earnings data on Thursday, January 31st. The medical equipment provider reported $0.97 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.94 by $0.03. ABIOMED had a net margin of 30.12% and a return on equity of 20.31%. The business had revenue of $200.56 million during the quarter, compared to analysts’ expectations of $200.60 million. On average, analysts expect that ABIOMED, Inc. will post 3.58 EPS for the current fiscal year.

Several equities research analysts recently weighed in on ABMD shares. BidaskClub cut shares of ABIOMED from a “hold” rating to a “sell” rating in a research report on Thursday, March 7th. ValuEngine cut shares of ABIOMED from a “buy” rating to a “hold” rating in a research report on Wednesday, February 27th. Zacks Investment Research raised shares of ABIOMED from a “hold” rating to a “buy” rating and set a $393.00 price objective for the company in a research report on Monday, February 4th. BTIG Research reaffirmed a “buy” rating and set a $400.00 price objective on shares of ABIOMED in a research report on Tuesday, January 22nd. They noted that the move was a valuation call. Finally, Morgan Stanley cut their price objective on shares of ABIOMED from $496.00 to $461.00 and set an “overweight” rating for the company in a research report on Wednesday, January 2nd. One analyst has rated the stock with a sell rating, one has given a hold rating and six have issued a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $421.00.

In other ABIOMED news, COO David M. Weber sold 24,000 shares of the business’s stock in a transaction dated Friday, January 25th. The stock was sold at an average price of $351.47, for a total transaction of $8,435,280.00. Following the completion of the transaction, the chief operating officer now owns 161,842 shares of the company’s stock, valued at $56,882,607.74. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Martin P. Sutter sold 5,985 shares of the business’s stock in a transaction dated Wednesday, February 6th. The stock was sold at an average price of $349.49, for a total value of $2,091,697.65. Following the transaction, the director now directly owns 212,943 shares of the company’s stock, valued at approximately $74,421,449.07. The disclosure for this sale can be found here. Insiders have sold 74,928 shares of company stock valued at $26,515,812 in the last ninety days. 3.50% of the stock is currently owned by company insiders.

WARNING: This report was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this report on another publication, it was illegally copied and republished in violation of international trademark & copyright laws. The original version of this report can be viewed at https://www.dispatchtribunal.com/2019/03/15/commonwealth-equity-services-llc-raises-holdings-in-abiomed-inc-abmd.html.

About ABIOMED

ABIOMED, Inc engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides continuum of care to heart failure patients. The company offers Impella 2.5 catheter, a percutaneous micro heart pump with integrated motor and sensors for use in interventional cardiology; and Impella CP, a device used by interventional cardiologists to support patients in the cath lab and cardiac surgeons in the heart surgery suite.

See Also: What is a Swap?

Institutional Ownership by Quarter for ABIOMED (NASDAQ:ABMD)

Receive News & Ratings for ABIOMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABIOMED and related companies with MarketBeat.com's FREE daily email newsletter.




Leave a Reply